Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2314
Predicate | Object |
---|---|
rdf:type | |
rdfs:label |
ERYTHROMYCIN ETHYLSUCCINATE (Suspension)
|
dailymed-instance:dosage |
Erythromycin ethylsuccinate suspensions may be administered
without regard to meals.<br/>Children: Age, weight and severity of the infection are important
factors in determining the proper dosage. In mild to moderate infections
the usual dosage of erythromycin ethylsuccinate for children is 30 to 50 mg/kg/day
in equally divided doses every 6 hours. For more severe infections this dosage
may be doubled. If twice-a-day dosage is desired, one-half of the total daily
dose may be given every 12 hours. Doses may also be given three times daily
by administering one-third of the total daily dose every 8 hours. The following dosage schedule is suggested for mild to moderate
infections:<br/>Adults: 400 mg erythromycin ethylsuccinate every 6 hours
is the usual dose. Dosage may be increased up to 4 g per day according to
the severity of the infection. If twice-a-day dosage is desired, one-half
of the total daily dose may be given every 12 hours. Doses may also be given
three times daily by administering one-third of the total daily dose every
8 hours. For adult dosage calculation, use
a ratio of 400 mg of erythromycin activity as the ethylsuccinate to 250 mg
of erythromycin activity as the stearate, base or estolate. In the treatment of streptococcal infections, a therapeutic
dosage of erythromycin ethylsuccinate should be administered for at least
10 days. In continuous prophylaxis against recurrences of streptococcal infections
in persons with a history of rheumatic heart disease, the usual dosage is
400 mg twice a day.<br/>For Treatment of Urethritis Due to C.
trachomatis or U. urealyticum: 800 mg three times a day for 7 days.<br/>For Treatment of Primary Syphilis:<br/>Adults: 48 to 64 g given in divided doses over a period
of 10 to 15 days.<br/>For Intestinal Amebiasis:<br/>Adults: 400 mg four times daily for 10 to 14 days. Children30 to 50 mg/kg/day in divided doses for 10
to 14 days.<br/>For Use in Pertussis: Although optimal dosage and duration have not been
established, doses of erythromycin utilized in reported clinical studies were
40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.<br/>For Treatment of Legionnaires' Disease: Although optimal doses have not been established,
doses utilized in reported clinical data were those recommended above (1.6 to
4 g daily in divided doses.)
|
dailymed-instance:descripti... |
Erythromycin is produced by a strain of Saccharopolyspora
erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics. It is basic
and readily forms salts with acids. The base, the stearate salt and the esters
are poorly soluble in water. Erythromycin ethylsuccinate is an ester of erythromycin
suitable for oral administration. Erythromycin ethylsuccinate oral suspension
contains 200 or 400 mg erythromycin activity per teaspoonful (5 mL) in a premixed
suspension with a cherry flavor, supplied in pint (16 fl oz) bottles. The
premixed suspension for oral administration is intended primarily for pediatric
use but can also be used in adults. Erythromycin
ethylsuccinate is known chemically as erythromycin 2'-(ethylsuccinate).
The molecular formula is CHNOand the
molecular weight is 862.06. The structural formula is:<br/>Inactive Ingredients: Alcohol less than 0.1%, citric acid, D&C Red
No. 33, FD&C Red No. 40, methylparaben, polysorbate 60, propylparaben,
sodium chloride, sodium citrate, sucrose, water, xanthan gum, and natural
and artificial flavoring.
|
dailymed-instance:clinicalP... |
Orally administered erythromycin ethylsuccinate suspension
is readily and reliably absorbed. Comparable serum levels of erythromycin
are achieved in the fasting and nonfasting states. Erythromycin
diffuses readily into most body fluids. Only low concentrations are normally
achieved in the spinal fluid, but passage of the drug across the blood-brain
barrier increases in meningitis. In the presence of normal hepatic function,
erythromycin is concentrated in the liver and excreted in the bile; the effect
of hepatic dysfunction on excretion of erythromycin by the liver into the
bile is not known. Less than 5 percent of the orally administered dose of
erythromycin is excreted in active form in the urine. Erythromycin
crosses the placental barrier, but fetal plasma levels are low. The drug
is excreted in human milk.<br/>Microbiology: Erythromycin acts by inhibition of protein synthesis
by binding 50 S ribosomal subunits
of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism
has been demonstrated in vitro between
erythromycin and clindamycin, lincomycin, and chloramphenicol. Many strains of Haemophilus
influenzae are resistant to erythromycin alone, but are susceptible
to erythromycin and sulfonamides used concomitantly. Staphylococci
resistant to erythromycin may emerge during a course of therapy. Erythromycin has been shown to be active against most strains
of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS
AND USAGE section.<br/>Gram-positive Organisms: Corynebacterium
diphtheriae Corynebacterium minutissimum Listeria
monocytogenes Staphylococcus aureus (resistant
organisms may emerge during treatment) Streptococcus pneumoniae Streptococcus
pyogenes<br/>Gram-negative Organisms: Bordetella
pertussis Legionella pneumophila Neisseria gonorrhoeae<br/>Other Microorganisms: Chlamydia
trachomatis Entamoeba histolytica Mycoplasma
pneumoniae Treponema pallidum Ureaplasma urealyticum The following in vitro data are available, but their clinical significance is unknown. Erythromycin exhibits in vitro minimal inhibitory concentrations (MIC's)
of 0.5��g/mL or less against most (���90%) strains of the following
microorganisms; however, the safety and effectiveness of erythromycin in treating
clinical infections due to these microorganisms have not been established
in adequate and well-controlled clinical trials.<br/>Gram-positive Organisms: Viridans
group streptococci<br/>Gram-negative Organisms: Moraxella
catarrhalis<br/>Susceptibility Tests:
|
dailymed-instance:activeIng... | |
dailymed-instance:contraind... |
Erythromycin is contraindicated in patients with known
hypersensitivity to this antibiotic. Erythromycin
is contraindicated in patients taking terfenadine, astemizole, pimozide, or
cisapride. (See PRECAUTIONS - Drug Interactions .)
|
dailymed-instance:supply |
Erythromycin ethylsuccinate oral suspension, USP,
400 mg erythromycin activity per teaspoonful (5 mL) is supplied in 1 pint
(473 mL) bottles (NDC 0074-3748-16). Erythromycin ethylsuccinate oral suspension, USP, 200 mg erythromycin
activity per teaspoonful (5 mL) is supplied in 1 pint (473 mL) bottles (NDC 0074-3747-16). Erythromycin
ethylsuccinate oral suspensions require refrigeration to preserve taste until
dispensed. Refrigeration by patient is not required if used within 14 days.
|
dailymed-instance:activeMoi... | |
dailymed-instance:inactiveI... |
dailymed-ingredient:Alcohol,
dailymed-ingredient:D&C_Red_No._33,
dailymed-ingredient:FD&C_Red_No._40,
dailymed-ingredient:citric_acid,
dailymed-ingredient:methylparaben,
dailymed-ingredient:natural_and_artificial_flavoring,
dailymed-ingredient:polysorbate_60,
dailymed-ingredient:propylparaben,
dailymed-ingredient:sodium_chloride,
dailymed-ingredient:sodium_citrate,
dailymed-ingredient:sucrose,
dailymed-ingredient:water,
dailymed-ingredient:xanthan_gum
|
dailymed-instance:overdosag... |
In case of overdosage, erythromycin should be discontinued.
Overdosage should be handled with the prompt elimination of unabsorbed drug
and all other appropriate measures should be instituted. Erythromycin is not removed by peritoneal dialysis or hemodialysis.
|
dailymed-instance:genericMe... |
erythromycin ethylsuccinate
|
dailymed-instance:fullName |
ERYTHROMYCIN ETHYLSUCCINATE (Suspension)
|
dailymed-instance:adverseRe... |
The most frequent side effects of oral erythromycin
preparations are gastrointestinal and are dose-related. They include nausea,
vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatitis, hepatic
dysfunction and/or abnormal liver function test results may occur. (See WARNINGS.) Onset of
pseudomembranous colitis symptoms may occur during or after antibiotic treatment.
(See WARNINGS.) Erythromycin
has been associated with QT prolongation and ventricular arrhythmias, including
ventricular tachycardia and torsades de pointes. Allergic reactions ranging from
urticaria to anaphylaxis have occurred. Skin reactions ranging from mild
eruptions to erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal
necrolysis have been reported rarely. There have been
rare reports of pancreatitis and convulsions. There
have been isolated reports of reversible hearing loss occurring chiefly in
patients with renal insufficiency and in patients receiving high doses of
erythromycin.
|
dailymed-instance:warning |
There have been reports of hepatic dysfunction, including
increased liver enzymes, and hepatocellular and/or cholestatic hepatitis,
with or without jaundice, occurring in patients receiving oral erythromycin
products. There have been reports suggesting
that erythromycin does not reach the fetus in adequate concentration to prevent
congenital syphilis. Infants born to women treated during pregnancy with
oral erythromycin for early syphilis should be treated with an appropriate
penicillin regimen. Pseudomembranous
colitis has been reported with nearly all antibacterial agents, including
erythromycin, and may range in severity from mild to life threatening. Therefore,
it is important to consider this diagnosis in patients who present with diarrhea
subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora
of the colon and may permit overgrowth of clostridia. Studies indicate that
a toxin produced by Clostridium difficile is
a primary cause of "antibiotic-associated colitis". After
the diagnosis of pseudomembranous colitis has been established, therapeutic
measures should be initiated. Mild cases of pseudomembranous colitis usually
respond to discontinuation of the drug alone. In moderate to severe cases,
consideration should be given to management with fluids and electrolytes,
protein supplementation, and treatment with an antibacterial drug clinically
effective against Clostridium difficile colitis. Rhabdomyolysis with or without renal impairment has been reported
in seriously ill patients receiving erythromycin concomitantly with lovastatin.
Therefore, patients receiving concomitant lovastatin and erythromycin should
be carefully monitored for creatine kinase (CK) and serum transaminase levels.
(See package insert for lovastatin.)
|
dailymed-instance:indicatio... |
To reduce the development of drug-resistant bacteria
and maintain the effectiveness of erythromycin ethylsuccinate oral suspension
and other antibacterial drugs, erythromycin ethylsuccinate oral suspension
should be used only to treat or prevent infections that are proven or strongly
suspected to be causedby susceptible bacteria. When culture and susceptibility
information are available, they should be considered in selecting or modifying
antibacterial therapy. In the absence of such data, local epidemiology and
susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate oral suspension is indicated in
the treatment of infections caused by susceptible strains of the designated
organisms in the diseases listed below: Upper
respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus
pneumoniae, Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since
many strains of H. influenzae are not
susceptible to the erythromycin concentrations ordinarily achieved). (See
appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity
caused by Streptococcus pneumoniae or Streptococcus pyogenes. Listeriosis
caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella
pertussis. Erythromycin is effective in eliminating the organism
from the nasopharynx of infected individuals, rendering them noninfectious.
Some clinical studies suggest that erythromycin may be helpful in the prophylaxis
of pertussis in exposed susceptible individuals. Respiratory
tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections
of mild to moderate severity caused by Streptococcus
pyogenes or Staphylococcus aureus (resistant
staphylococci may emerge during treatment). Diphtheria:
Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers
and to eradicate the organism in carriers. Erythrasma:
In the treatment of infections due to Corynebacterium
minutissimum. Intestinal amebiasis
caused by Entamoeba histolytica (oral
erythromycins only). Extraenteric amebiasis requires treatment with other
agents. Acute pelvic inflammatory disease caused
by Neisseria gonorrhoeae: As an alternative
drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history
of sensitivity to penicillin. Patients should have a serologic test for syphilis
before receiving erythromycin as treatment of gonorrhea and afollow-up serologic
test for syphilis after 3 months. Syphilis caused
by Treponema pallidum: Erythromycin
is an alternate choice of treatment for primary syphilis in patients allergic
to the penicillins. In treatment of primary syphilis, spinal fluid examinations
should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following
infections caused by Chlamydia trachomatis:
conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections
during pregnancy. When tetracyclines are contraindicated or not tolerated,
erythromycin is indicated for the treatment of uncomplicated urethral, endocervical,
or rectal infections in adults due to Chlamydia
trachomatis. When tetracyclines are
contraindicated or not tolerated, erythromycin is indicated for the treatment
of nongonococcal urethritis caused by Ureaplasma
urealyticum. Legionnaires' Disease
caused by Legionella pneumophila.
Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data
suggest that erythromycin may be effective in treating Legionnaires'
Disease.<br/>Prophylaxis:<br/>Prevention of Initial Attacks of Rheumatic Fever: Penicillin is considered by the American Heart
Association to be the drug of choice in the prevention of initial attacks
of rheumatic fever (treatment of Streptococcus
pyogenes infections of the upper respiratory tract e.g., tonsillitis
or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic
patients.The therapeutic dose should be administered for 10
days.<br/>Prevention of Recurrent Attacks of Rheumatic Fever: Penicillin or sulfonamides are considered by the
American Heart Association to be the drugs of choice in the prevention of
recurrent attacks of rheumatic fever. In patients who are allergic to penicillin
and sulfonamides, oral erythromycin is recommended by the American Heart Association
in the long-term prophylaxis of streptococcal pharyngitis (for the prevention
of recurrent attacks of rheumatic fever).
|
dailymed-instance:represent... | |
dailymed-instance:routeOfAd... | |
dailymed-instance:name |
ERYTHROMYCIN ETHYLSUCCINATE
|